Kyntra Bio (KYNB) Other Non-Current Liabilities (2014 - 2026)
Kyntra Bio (KYNB) posted Other Non-Current Liabilities of $76000.0 for Q1 2026, down 7.32% sequentially from $82000.0 in Q4 2025, and down 90.84% YoY from $830000.0 in Q1 2025.
Kyntra Bio (KYNB) Other Non-Current Liabilities (2014 - 2026) Analysis & Trends
Kyntra Bio has reported Other Non-Current Liabilities for 13 years, with the latest figure at $76000.0 in Q1 2026.
- Quarterly Other Non-Current Liabilities fell 90.84% year-over-year to $76000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $76000.0 (down 90.84% YoY) and the FY2025 annual result came in at $82000.0, down 90.02% from the prior year.
- Other Non-Current Liabilities declined to $76000.0 in Q1 2026 per KYNB's latest filing, from $82000.0 in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $24.3 million in Q1 2022 and troughed at $76000.0 in Q1 2026.
- A 5-year average of $5.3 million and a median of $2.9 million in 2023 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2022 and 2026: Other Non-Current Liabilities soared 2333.0% in 2022, then tumbled 90.84% in 2026.
- Over 5 years, Other Non-Current Liabilities stood at $6.4 million in 2022, then tumbled by 55.62% to $2.9 million in 2023, then sank by 71.24% to $822000.0 in 2024, then slumped by 90.02% to $82000.0 in 2025, then decreased by 7.32% to $76000.0 in 2026.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $76000.0, $82000.0, and $98000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Kyntra Bio | 30.42 Mn | 30.42 Mn | 1.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 67,000.00 |
| Mar 31, 2026 | 76,000.00 |
| Dec 31, 2025 | 82,000.00 |
| Sep 30, 2025 | 98,000.00 |
| Jun 30, 2025 | 106,000.00 |
| Mar 31, 2025 | 830,000.00 |
| Dec 31, 2024 | 822,000.00 |
| Sep 30, 2024 | 837,000.00 |
| Jun 30, 2024 | 1.01 Mn |
| Mar 31, 2024 | 3.79 Mn |
| Dec 31, 2023 | 2.86 Mn |
| Sep 30, 2023 | 4.26 Mn |
| Jun 30, 2023 | 4.96 Mn |
| Mar 31, 2023 | 7.06 Mn |
| Dec 31, 2022 | 6.44 Mn |
| Sep 30, 2022 | 14.30 Mn |
| Jun 30, 2022 | 17.83 Mn |
| Mar 31, 2022 | 24.33 Mn |
| Dec 31, 2021 | 26.02 Mn |
| Sep 30, 2021 | 1.69 Mn |